Author

J. Sarry

h-index 45 View on Semantic Scholar

We have 3 of 169 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models.

Preclinical development of LY3410738, an oral, dual IDH1/2 inhibitor with potential to penetrate the blood-brain barrier is presented, which synergized and was well tolerated with standard-of-care regimens such as cytarabine, azacitidine, venetoclax, or midostaurin in IDH1/2-mutated AML PDXs.

Nathan A Brooks, Anna Skwarska, V. Salama et al. · Blood Cancer Discovery · 0 citations

Open access Aug 2026

Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia

It is shown that leukemic propagation is driven by a non-genetic remodeling program, providing a framework to prioritize and test stage-specific therapeutic strategies in AML.

Clément Larrue, Paolo Angelino, Sarah Mouche et al. · Cell Reports Medicine · 0 citations

Open access Aug 2026

A PTBP1–CDC42 splicing axis regulates leukemia growth and venetoclax sensitivity in acute myeloid leukemia

PTBP1 is established as a critical regulator of AML cell fitness and a clinically actionable therapeutic combination that exploits AML dependency on PTBP1-CDC42 signaling to enhance the efficacy of venetoclax-based regimens is identified.

Margaux Oberling, Mathieu Landry, Yann Aubert et al. · bioRxiv · 0 citations